Metastatic disease is responsible for approximately 90% of cancer deaths. For successful
dissemination and metastasis, cancer cells must evade detection and destruction by the …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …

Myeloid-derived suppressor cells (MDSCs) have emerged as major regulators of immune
responses in cancer and other pathological conditions. In recent years, ample evidence …

Myeloid-derived suppressor cells (MDSC) are a diverse population of immature myeloid
cells that have potent immune-suppressive activity. Studies in both mice and humans have …

Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves
administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT …

The advent of immunotherapy, especially checkpoint inhibitor-based immunotherapy, has
provided novel and powerful weapons against cancer. Because only a subset of cancer …

Tumour-induced granulocytic hyperplasia is associated with tumour vasculogenesis and
escape from immunity via T cell suppression. Initially, these myeloid cells were identified as …

Anticancer agents continue to dominate the list of newly approved drugs, approximately half
of which are immunotherapies. This trend illustrates the considerable promise of cancer …

Abstract Traditional Chinese Medicine (TCM) has been traditionally used to treat patients
with cancers in China. It not only alleviates the symptoms of tumor patients and improves …